BridgeMD
New treatment option for Myopia, Child Myopia Progression
Official title Effect of MiYOSMART iQ Spectacle Lenses on Myopia Progression in Children
ClinicalTrials.gov ID: NCT07387159
What this study is testing
- What it's testing
- This prospective, single-center study aims to evaluate the efficacy and safety of MiYOSMART iQ spectacle lenses with DIMS (Defocus Incorporated Multiple Segments) and Triple Enhanced Design (TED) technology in slowing myopia progression in children aged 8-11 years. 35 children with myopia (spherical equivalent -0.5 to -6.0 D) will be prescribed MiYOSMART iQ lenses and followed for 6 months.
- Time commitment: about 6 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 8 to 11
You may be able to join if
- Age 8-11 years (inclusive)
- Myopia: spherical equivalent -0.5 to -6.0 D under cycloplegia
- No previous myopia control treatment
- Orthophoria, presence of binocular vision
You likely can't join if
- Corrected visual acuity \< 0.8 (decimal)
- Anisometropia \> 2.0 D
- Strabismus history or presence
- Previous refractive or intraocular surgery
The study team makes the final eligibility decision.
Where it's taking place
- Moscow, Russia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 6 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 8 years to 11 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Moscow, Russia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.